ArticleScientific reports2025
Exploration of common pathogenic genes between cerebral amyloid angiopathy and insomnia based on bioinformatics and experimental validation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cerebral amyloid angiopathy (CAA) and insomnia are age-related neurological disorders increasingly recognized as being closely associated. However, research on the shared genes and their biological mechanisms remains limited. This study aims to identify common genes between CAA and insomnia and explore their potential molecular mechanisms, offering new insights for diagnosis and treatment. Blood samples were collected from 11 CAA patients and 11 healthy controls, followed by RNA sequencing (RNA-seq). Additionally, the microarray dataset GSE208668 for the insomnia cohort was downloaded from the Gene Expression Omnibus (GEO) database. Differential expression analysis was performed to identify common differentially expressed genes (DEGs). Protein-protein interaction (PPI) networks and machine learning methods Random Forest (RF) and Extreme Gradient Boosting (XGBoost) were used to narrow down key genes. We explored the biological functions of these genes through immune cell infiltration, metabolic and Hallmark pathway analyses, and clinical correlation analysis. Co-expression networks, drug-mRNA networks, transcription factor (TF)-mRNA-miRNA networks, and competing endogenous RNA (ceRNA) networks were also constructed. Finally, hub gene expression patterns were analyzed using the Human Protein Atlas (HPA) database, and validation was performed in clinical samples and animal models using quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) and Western blot. Differential expression analysis identified 185 DEGs. PPI network construction and machine learning methods identified CBX5 and POLR1B as common hub genes for both insomnia and CAA. Immune infiltration, metabolic, and Hallmark pathway analyses revealed these hub genes play distinct roles in each disease. Various network models were constructed to explore their regulatory mechanisms. The reliability of the hub genes was validated using bioinformatics analyses and experimental approaches. This study, combining bioinformatics and experimental validation, identifies CBX5 and POLR1B as shared hub genes for CAA and insomnia. These findings offer new molecular targets for the diagnosis and treatment of both diseases, providing a foundation for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.